Neuroprotective effect of histamine H3 receptor blockade on methamphetamine-induced cognitive impairment in mice

• Published in: Pharmacology, biochemistry and behavior Vol. 222; p. 173512
• Main Authors: Luo, Hu, Li, Xiaofang, Fan, Runyue, Ruan, Yuer, Qian, Liyin, Shen, Yao, Si, Zizhen, Li, Longhui, Liu, Yu
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2023
• Subjects: Animals; Cognitive Dysfunction; Cognitive impairment; Histamine; Histamine H3 receptor; Memory Disorders - chemically induced; Methamphetamine; Mice; Mice, Inbred C57BL; Neuroprotective Agents - pharmacology; Neurotoxicity; Receptors, Histamine H3 - metabolism; Neurotoxicity; Histamine H3 receptor; Methamphetamine; Cognitive impairment
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/j.pbb.2022.173512

Methamphetamine (METH) exposure is commonly believed to result in cognitive impairment. Histamine H3 receptor (H3R) antagonists reportedly have potential applications for treating cognitive impairment accompanied by various neuropsychiatric disorders. The present study aimed to investigate the effect of H3R blockade by Thioperamide (THIO) on METH-induced cognitive impairment and the underlying mechanism. In Experiment 1, C57BL/6 mice received daily injections of saline or 5 mg/kg METH for 5 consecutive days. The Novel Object Recognition (NOR) and Morris water maze (MWM) tasks were used to assess cognitive functions of mice. H3R protein expression and apoptosis were subsequently measured in the hippocampus. In Experiment 2, HT22 cells were first treated with ddH2O or 3 mM METH. The cell survival rate and H3R protein level were subsequently assessed. In Experiment 3, the animals were first treated with saline or 20 mg/kg THIO for 7 days, followed by co-administration of either saline or 5 mg/kg METH for an additional 5 days. The remaining experiments were carried out in the same manner as Experiment 1. In Experiment 4, HT22 cells were pretreated with either ddH2O or 5 mM THIO for 2 h, followed by ddH2O or 3 mM METH treatment for an additional 12 h. The remaining experiments were carried out in the same manner as Experiment 2. In Experiment 5, the changes in MEK1/2, p-MEK1/2, ERK1/2 and p-ERK1/2 protein levels were examined in the hippocampus of all mice from Experiment 3 and HT22 cells from Experiment 4. METH-treated mice showed significantly worsened NOR and MWM performance, along with markably hippocampal apoptosis. A significantly lower cell survival rate was observed in METH-treated HT22 cells. Increased levels of H3R protein were found in both METH-treated mice and HT22 cells. THIO significantly improved METH-induced cognitive impairment in mice and toxicity in HT22 cells. METH significantly increased the level of p-MEK1/2 and p-ERK1/2 proteins in the hippocampus of mice and HT22 cells, which was reversed by THIO pretreatment. Our findings reveal that H3R blockade by THIO yields a neuroprotective effect against METH-induced cognitive impairment in mice and toxicity in HT22 cells via the raf-MEK-ERK signaling pathway. •Methamphetamine (METH) treatment induced cognitive impairment in mice and toxicity in HT22 cells•H3R protein expression was increased in the hippocampus of METH-treated mice and HT22 cells•H3R blockade by THIO improved METH-induced cognitive impairment in mice and toxicity in HT22 cells•THIO treatment altered the increased p-MEK1/2 and p-ERK1/2 protein levels in the hippocampus of mice and HT22 cells•H3R blockade by THIO may provide a protective effect against METH-induced cognitive impairment.